Pulse Biosciences saw a notable intraday rise in its share price, gaining 8.3% in mid-day trading after Freedom Capital Markets analyst Keith Hinton began coverage with a Buy rating and set a $73 price target. The analyst note renewed investor focus on the bioelectric medicine firm and its clinical program in atrial fibrillation ablation.
Hinton’s initiation centers on the company’s nanosecond pulsed field ablation - nsPFA - platform and the addressable market for atrial fibrillation ablation, which he characterizes as large, expanding, and open to disruption by new approaches. The analyst also emphasized Pulse Biosciences’ financial position and strategic posture as sufficient to carry the company into a critical upcoming data milestone.
At the core of the thesis is the NANOPULSE-AF trial. Freedom Capital Markets noted that if the trial data meet expectations - with results anticipated around the second quarter of 2027 - multiple potential acquirers could become interested in the company in the second half of 2027 or earlier. That potential for acquisition optionality, the note said, is a material element of the investment case.
Adding to confidence in the program timeline, the NANOPULSE-AF study has reportedly passed its enrollment midpoint. That progress, together with the analyst initiation and its price target well above current trading levels, has been interpreted by market participants as a meaningful near-term catalyst.
Market observers also pointed to insider activity as a reinforcing signal. The company’s chief operating officer made an open-market purchase of shares in early September, an action that has drawn attention from investors assessing insider conviction.
The broader U.S. market provided no obvious lift for Pulse Biosciences on the day. The S&P 500, Dow Jones and Nasdaq were trading modestly lower, a dynamic that underscores the company-specific drivers behind PLSE’s move rather than sector- or market-wide momentum.
On the price history front, the stock is trading near its 52-week peak of $58.90, a level it briefly reached in the prior session. That peak marks a substantial multi-month advance from a 52-week low of $12.56 and highlights the recent strength in the shares.
In sum, the combination of a high-conviction analyst initiation with an above-market price target, accelerating clinical enrollment, and recent insider buying has created a concentrated set of near-term catalysts for Pulse Biosciences. Those factors have helped the stock stand out on a day when major indices were softer, and they underpin investor interest ahead of the company’s key clinical readout timeline.